Nitazenes are a class of synthetic opioids that were developed in the 1950s as experimental painkillers but never approved for any medical use. They have resurfaced in the illicit drug supply over the past several years, with some variants reaching potencies up to 500 times that of morphine. Their emergence has driven a wave of overdose deaths across the United States and the United Kingdom, making them one of the most dangerous drug classes currently circulating.
How Nitazenes Work in the Body
Like morphine, heroin, and fentanyl, nitazenes activate the same pain-relieving receptor in the brain. The difference is how tightly and efficiently they bind to it. Researchers measure this by looking at how little of a substance is needed to activate that receptor. Fentanyl and morphine require roughly similar concentrations. Isotonitazene, one of the more common nitazenes, activates the receptor at a concentration about 15 times lower than fentanyl. Some newer variants are even more extreme: one called N-desethyl isotonitazene activates the receptor at a concentration roughly 400 times lower than fentanyl.
This extreme binding efficiency is what makes nitazenes so dangerous. A quantity invisible to the naked eye can trigger the same cascade of effects as a much larger dose of heroin or fentanyl: pain suppression, sedation, euphoria, and critically, slowed breathing. Because the doses involved are so tiny, even small inconsistencies in how a drug is mixed can mean the difference between intoxication and fatal respiratory failure.
Potency Compared to Other Opioids
Not all nitazenes are equally potent. The class spans a wide range, with some members comparable to fentanyl and others far stronger. Using heroin as a baseline:
- Fentanyl: roughly 50 times the potency of heroin
- Metonitazene: roughly 50 times heroin (similar to fentanyl)
- Protonitazene: roughly 100 times heroin
- Isotonitazene: roughly 250 times heroin
- Etonitazene: roughly 500 times heroin
These are estimates based on preclinical data, and real-world effects depend on many factors. But the key point is that even the “weaker” nitazenes are comparable to fentanyl, and the strongest ones dwarf it. Lab studies found that 10 of the nitazene variants tested had significantly higher potency than fentanyl at the receptor level. Some newer structural modifications, where chemists tweak the molecule slightly, have produced variants even more potent than their parent compounds.
Where They Came From
Nitazenes were first synthesized in the 1950s by researchers at the Swiss pharmaceutical company Ciba as part of a search for new painkillers. The compounds were studied in animals and shown to be powerful analgesics, but none were ever cleared for human use or brought to market. For decades, they existed only in old chemistry journals.
They began appearing in the illicit drug supply around 2019, when isotonitazene started showing up in overdose cases. After the U.S. scheduled isotonitazene in mid-2020, manufacturers shifted to alternatives. Metonitazene-related deaths began accumulating from late 2020 onward. By 2021 and 2022, a cascade of new analogs appeared: butonitazene, flunitazene, protonitazene, etonitazepyne, and others. Each time authorities scheduled one variant, underground chemists produced the next, exploiting the fact that slight molecular changes could create a technically unscheduled substance.
How Nitazenes Enter the Drug Supply
Nitazenes typically don’t reach users as a product someone deliberately seeks out. They show up as adulterants or substitutes mixed into other drugs, including heroin, counterfeit prescription pills, and sometimes other substances entirely. Because the active doses are measured in micrograms, a single gram of raw nitazene material can contaminate a large batch of product. People using what they believe is heroin or a pharmaceutical opioid may have no idea a nitazene is involved until something goes wrong.
Why Standard Drug Tests Miss Them
One of the most concerning aspects of nitazenes is how difficult they are to detect. Standard urine drug screens used in hospitals and clinics are designed to pick up common opioids like morphine, oxycodone, and sometimes fentanyl. Nitazenes have a different chemical backbone (a benzimidazole ring rather than the structures found in traditional opioids) and typically do not trigger a positive result on these routine tests.
Even in forensic laboratories, identification is challenging. Rapid screening tools like infrared spectroscopy and surface-enhanced Raman spectroscopy can flag the presence of a nitazene-type compound but often cannot distinguish between specific variants because many share similar spectral signatures. The gold standard for identification is liquid chromatography paired with mass spectrometry, which can separate and identify individual analogs, including trace quantities mixed with other drugs. This level of analysis is not available in most clinical settings, which means nitazene involvement in an overdose may go unrecognized unless specialized testing is specifically requested.
Naloxone Still Works, but More May Be Needed
The standard opioid overdose reversal drug, naloxone (sold as Narcan), is effective against nitazenes. It works by competing for the same receptor that nitazenes activate, displacing the drug and restoring breathing. However, because nitazenes bind so tightly to that receptor, multiple doses of naloxone are often required. The CDC has confirmed that naloxone can be safely administered in repeated doses for nitazene-involved overdoses, similar to the approach already used for fentanyl.
In a review of nitazene-involved fatal overdoses in Tennessee between 2019 and 2021, naloxone was administered to only 23% of those who died. This suggests that in many cases, no bystander or first responder was present, or the overdose was not recognized in time. The combination of extreme potency, rapid onset, and lack of awareness about nitazenes likely contributes to the low rate of intervention.
Recent Death Toll
Data from England illustrates how quickly the nitazene problem has grown. Between June 2023 and May 2024, lab-confirmed testing linked 179 deaths to one or more nitazenes. Protonitazene was the most commonly detected variant (73 deaths), followed by N-desethyl isotonitazene (46 deaths) and metonitazene (34 deaths). The shifting pattern of which variant dominates reflects how rapidly the supply changes as new analogs replace scheduled ones.
In the United States, comprehensive national data on nitazene-specific deaths remains limited because many coroner and medical examiner offices do not yet routinely test for these compounds. The true toll is almost certainly higher than reported figures suggest.
Legal Status
The DEA has placed multiple nitazene compounds into Schedule I of the Controlled Substances Act, the most restrictive category, reserved for substances with high abuse potential and no accepted medical use. Isotonitazene was the first to be scheduled. In July 2024, the DEA issued a temporary scheduling order adding N-desethyl isotonitazene and N-piperidinyl etonitazene to Schedule I, citing an imminent hazard to public safety. That order remains in effect for two years with a possible one-year extension while permanent scheduling proceeds.
The regulatory challenge is structural. The nitazene class contains dozens of possible analogs, and each new variant may require its own scheduling action. Clandestine chemists can stay a step ahead by producing compounds not yet explicitly listed, creating a cycle of emergence, detection, and regulation that has so far proved difficult to break.